Enzene Expands Hopewell Biologics CDMO Facility with 26,000 Sq Ft Addition

• Enzene has expanded its upcoming biologics CDMO facility in Hopewell, New Jersey by 26,000 square feet.

• The site will feature drug substance manufacturing suites, quality labs, and use the company’s proprietary EnzeneX™ 2.0 platform.

Enzene, a specialist in continuous biologics manufacturing, has expanded its upcoming contract manufacturing site in Hopewell, near Princeton, New Jersey. The company announced an additional 26,000 square feet of space to the already planned 54,000 square feet.

The enlarged site will now include extra drug substance manufacturing suites, laboratories, storage, and warehousing. Though the facility is yet to be officially launched, non-GMP batches are already being produced. “We will officially open our site later this year but are already producing non-GMP batches and seeing strong demand from U.S.-based small- and medium-sized innovators as we look ahead to GMP readiness,” said Norm Stoffregen, SVP and site head at Hopewell.

The expansion supports Enzene’s plans to meet growing demand from smaller U.S. biopharma clients. The company is integrating its EnzeneX™ 2.0 platform, which offers fully-connected continuous manufacturing (FCCM™) capabilities, enabling more compact, efficient operations.

The platform includes process analytical technology (PAT) for real-time control, and supports GMP supply at scales as low as 30 litres, with flexible bioreactor sizing for future growth. It is designed to reduce footprint while maintaining consistency and quality.